Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.50 |
| ▸ | LPL | P06858 | 2/20 | 0.50 |
| ▸ | HAT1 | O14929 | 7/20 | 0.41 |
| ▸ | EP300 | Q09472 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12374507 | 0.84 | MAPK14 (0.45) | LIPGLPLHAT1EP300KMT2A | |
| SCHEMBL2283542 | 0.82 | LIPG (0.41) | LIPGLPLEP300ROCK1CA1 | |
| SCHEMBL2145222 | 0.80 | LIPG (0.58) | LIPGLPLKMT2AMEN1CA1 | |
| SCHEMBL23071684 | 0.76 | LIPG (0.70) | LIPGLPL | |
| SCHEMBL11341183 | 0.76 | ULK1 (0.52) | HAT1EP300KMT2AMEN1ULK1 | |
| SCHEMBL11341169 | 0.76 | ULK1 (0.52) | HAT1EP300KMT2AMEN1ULK1 | |
| SCHEMBL901322 | 0.76 | LIPG (0.74) | LIPGLPL | |
| SCHEMBL16444822 | 0.75 | LIPG (0.52) | LIPGLPLKMT2AMEN1CA1 | |
| SCHEMBL16936864 | 0.73 | LIPG (0.74) | LIPGLPLROCK1 | |
| SCHEMBL108008 | 0.73 | LIPG (0.57) | LIPGLPLROCK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | LIPG 3194/4885LPL 2733/4885HAT1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.